US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alumis Inc.

4.28

-0.0300-0.70%

Post-market: 4.280.00000.00%19:50 EDT

Volume:181.49K

Turnover:774.50K

Market Cap:232.86M

PE:-0.41

High:4.49

Open:4.29

Low:4.16

Close:4.31

Loading ...

Overview Company News Filings

Oppenheimer Adjusts Price Target on Alumis to $26 From $32, Keeps Outperform Rating

MT Newswires Live

Alumis Inc. : Oppenheimer Cuts Target Price to $26 From $32

THOMSON REUTERS

Alumis price target lowered to $26 from $32 at Oppenheimer

Alumis Is Maintained at Buy by HC Wainwright & Co.

We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate

Simply Wall St.

BRIEF-Alumis, Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company

ACELYRIN, INC. Announces Merger with Alumis Inc.

Alumis Inc trading resumes

Alumis, Acelyrin to merge in all-stock transaction

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-Mediated Diseases

THOMSON REUTERS

Alumis Inc: Alumis & ACELYRIN Stockholders to Own About 55% & About 45%, Respectively, of Combined Co on Fully Diluted Basis

THOMSON REUTERS

Alumis Inc: Under Deal, ACELYRIN Stockholders to Receive 0.4274 Shares of Alumis Common Stock for Each Share of ACELYRIN Common Stock Owned

THOMSON REUTERS

Alumis Inc: Alumis & ACELYRIN's Combined Pro Forma Cash Position of About $737 Mln as of Dec 31, 2024, Provides Runway Into 2027

THOMSON REUTERS

Alumis Inc: Combined Company Will Operate Under Alumis Name With Current Alumis Executive Team

THOMSON REUTERS

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Oppenheimer Initiates Coverage on Alumis With Outperform Rating, $32 Price Target

MT Newswires Live

Alumis initiated with an Outperform at Oppenheimer

Alumis Strengthens Leadership Team With Key Appointments

THOMSON REUTERS

Alumis Strengthens Leadership Team with Key Appointments

Alumis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ALMS/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":4.28,"timestamp":1745611200000,"preClose":4.31,"halted":0,"volume":181491,"hourTrading":{"tag":"盘后","latestPrice":4.28,"preClose":4.28,"latestTime":"19:50 EDT","volume":1161,"amount":4970.348,"timestamp":1745625044435},"delay":0,"floatShares":4764683,"shares":54407327,"eps":-10.381567,"marketStatus":"Market Closed","change":-0.03,"latestTime":"04-25 16:00:00 EDT","open":4.29,"high":4.4884,"low":4.16,"amount":774495.7823460001,"amplitude":0.076195,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.381567,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":4.31,"preHourTrading":{"tag":"盘前","latestPrice":4.36,"preClose":4.31,"latestTime":"09:29 EDT","volume":122,"amount":540.441944,"timestamp":1745587799998},"postHourTrading":{"tag":"盘后","latestPrice":4.28,"preClose":4.28,"latestTime":"19:50 EDT","volume":1161,"amount":4970.348,"timestamp":1745625044435},"volumeRatio":0.5495577276056506,"impliedVol":0.8308,"impliedVolPercentile":0.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":4764683,"roa":"-87.31%","roe":"-198.66%","lyrEps":-10.381567,"volumeRatio":0.5495577276056506,"shares":54407327,"dividePrice":0,"high":4.4884,"amplitude":0.076195,"preClose":4.31,"low":4.16,"week52Low":3.18,"pbRate":"0.90","week52High":13.53,"institutionHeld":0,"latestPrice":4.28,"eps":-10.381567,"divideRate":0,"volume":181491,"delay":0,"ttmEps":-10.381567,"open":4.29,"prevYearClose":7.86,"prevWeekClose":5,"prevMonthClose":6.14,"prevQuarterClose":6.14,"fiveDayClose":5,"twentyDayClose":4.7,"sixtyDayClose":6.53},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510863958","title":"Oppenheimer Adjusts Price Target on Alumis to $26 From $32, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2510863958","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510863958?lang=en_us&edition=fundamental","pubTime":"2025-02-10 22:41","pubTimestamp":1739198468,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) has an average rating of buy and mean price target of $22.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS","OPY"],"gpt_icon":0},{"id":"2510546218","title":"Alumis Inc. : Oppenheimer Cuts Target Price to $26 From $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2510546218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510546218?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:04","pubTimestamp":1739192697,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nAZN3BUEYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2510121854","title":"Alumis price target lowered to $26 from $32 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2510121854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510121854?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:55","pubTimestamp":1739192154,"startTime":"0","endTime":"0","summary":"Oppenheimer lowered the firm’s price target on Alumis (ALMS) to $26 from $32 and keeps an Outperform rating on the shares. The firm says the reduct...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-26-from-32-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-26-from-32-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","ALMS"],"gpt_icon":0},{"id":"2509974810","title":"Alumis Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2509974810","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509974810?lang=en_us&edition=fundamental","pubTime":"2025-02-07 20:38","pubTimestamp":1738931880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 07, 2025 07:38 ET (12:38 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2509716061","title":"We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2509716061","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509716061?lang=en_us&edition=fundamental","pubTime":"2025-02-07 18:36","pubTimestamp":1738924583,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.So, the natural question for Alumis  shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.Alumis has a market capitalisation of US$388m and burnt through US$217m last year, which is 56% of the company's market value. From this perspective, it seems that the company spent a huge amount relative to its market value, and we'd be very wary of a painful capital raising.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-keeping-eye-alumis-nasdaq-103623677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","QID","QLD","LU2095319765.USD","BK4112","BK4007","PSQ","IE00BKPKM429.USD","TQQQ","BK4585","IE00B64PRP62.GBP","ALMS","NQmain","TSYW.SI","SQQQ",".IXIC","MNQmain","LU2210149790.SGD","NVIW.SI","IE00BGHQF748.EUR","LU2210150020.SGD","NDAQ","IE00B3QW5Z07.USD","USAW.SI","BK4588"],"gpt_icon":1},{"id":"2509738063","title":"BRIEF-Alumis, Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2509738063","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509738063?lang=en_us&edition=fundamental","pubTime":"2025-02-07 06:56","pubTimestamp":1738882592,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis, Acelyrin To Merge Creating A Late-Stage Clinical Biopharma CompanyFeb 6 (Reuters) - Alumis Inc ALMS.O:ALUMIS AND ACELYRIN TO MERGE CREATING A LATE-STAGE CLINICAL BIOPHARMA COMPANY DEDICA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA8MVLBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4139","SLRN","BK4007"],"gpt_icon":0},{"id":"2509735302","title":"ACELYRIN, INC. Announces Merger with Alumis Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2509735302","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509735302?lang=en_us&edition=fundamental","pubTime":"2025-02-07 06:50","pubTimestamp":1738882230,"startTime":"0","endTime":"0","summary":"ACELYRIN, INC. ( ($SLRN) ) just unveiled an announcement. On February 6, 2025, ACELYRIN, INC. and Alumis Inc. announced a definitive merger agreeme...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acelyrin-inc-announces-merger-with-alumis-inc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acelyrin-inc-announces-merger-with-alumis-inc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INC","SLRN","BK4139","ALMS","BK4007"],"gpt_icon":0},{"id":"2509782657","title":"Alumis Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2509782657","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509782657?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:45","pubTimestamp":1738878310,"startTime":"0","endTime":"0","summary":"16:45 EST Alumis (ALMS) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2509638782","title":"Alumis, Acelyrin to merge in all-stock transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2509638782","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509638782?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:40","pubTimestamp":1738878022,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) and Acelyrin (SLRN) announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock transaction. A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-acelyrin-to-merge-in-all-stock-transaction?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-acelyrin-to-merge-in-all-stock-transaction?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS","BK4139","SLRN"],"gpt_icon":0},{"id":"2509124781","title":"Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-Mediated Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2509124781","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509124781?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA8MVLBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007","SLRN","BK4139"],"gpt_icon":0},{"id":"2509781299","title":"Alumis Inc: Alumis & ACELYRIN Stockholders to Own About 55% & About 45%, Respectively, of Combined Co on Fully Diluted Basis","url":"https://stock-news.laohu8.com/highlight/detail?id=2509781299","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509781299?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA6JLCGT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4139","SLRN","BK4007"],"gpt_icon":0},{"id":"2509781050","title":"Alumis Inc: Under Deal, ACELYRIN Stockholders to Receive 0.4274 Shares of Alumis Common Stock for Each Share of ACELYRIN Common Stock Owned","url":"https://stock-news.laohu8.com/highlight/detail?id=2509781050","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509781050?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA6JLCGT:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","ALMS","SLRN"],"gpt_icon":0},{"id":"2509778105","title":"Alumis Inc: Alumis & ACELYRIN's Combined Pro Forma Cash Position of About $737 Mln as of Dec 31, 2024, Provides Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2509778105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509778105?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA6JLCGT:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLRN","ALMS","BK4007"],"gpt_icon":0},{"id":"2509292781","title":"Alumis Inc: Combined Company Will Operate Under Alumis Name With Current Alumis Executive Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2509292781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509292781?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA6JLCGT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007","SLRN","BK4139"],"gpt_icon":0},{"id":"2509781045","title":"Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2509781045","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509781045?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876500,"startTime":"0","endTime":"0","summary":"Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026. Evaluation underway of development plan for ACELYRIN’s lonigutamab to confirm differentiation in a capital efficient manner. Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis. Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the Board Transaction Committee, said, “This merger represents the culmination of a thorough strategic review process by our Board and management team to determine the best and most value-maximizing path forward for ACELYRIN. We are confident that Alumis is the right partner to optimize the development of lonigutamab and together deliver long-term stockholder value.”“We are pleased to join with Alumis and further advance our mission of develop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alumis-acelyrin-merge-creating-stage-211500228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALMS","SLRN","BK4007","SSI"],"gpt_icon":0},{"id":"2507362835","title":"Oppenheimer Initiates Coverage on Alumis With Outperform Rating, $32 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2507362835","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507362835?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:06","pubTimestamp":1738242386,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) has an average rating of Buy and mean price target of $30.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","ALMS"],"gpt_icon":0},{"id":"2507429526","title":"Alumis initiated with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2507429526","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507429526?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:06","pubTimestamp":1738238788,"startTime":"0","endTime":"0","summary":"Oppenheimer initiated coverage of Alumis (ALMS) with an Outperform rating and $32 price target The company is focused on delivering “class-leading”...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","OPY"],"gpt_icon":0},{"id":"2506351806","title":"Alumis Strengthens Leadership Team With Key Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2506351806","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506351806?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:00","pubTimestamp":1738069201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nTUA6SMJM2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2506513567","title":"Alumis Strengthens Leadership Team with Key Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2506513567","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506513567?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:00","pubTimestamp":1738069200,"startTime":"0","endTime":"0","summary":"Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies at global biopharmaceutical companiesSara Klein promoted","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/28/3016314/0/en/Alumis-Strengthens-Leadership-Team-with-Key-Appointments.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS","BK4120","TISI"],"gpt_icon":0},{"id":"2501233514","title":"Alumis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2501233514","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501233514?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:02","pubTimestamp":1736164920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2025 07:02 ET (12:02 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":99,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2025-04-24","current":-0.870937,"percent":0.963351,"low":-5.220865,"twenty":-3.461615,"median":-2.006318,"eighty":-1.170751,"high":-0.660137,"avg":-2.364432,"sd":1.067026,"marketCap":256258510},"quantilePoints":[{"date":"2024-06-28","current":-5.220865,"twenty":-5.220865,"median":-5.220865,"eighty":-5.220865,"marketCap":881360393},{"date":"2024-07-05","current":-3.577828,"twenty":-4.31182,"median":-3.851156,"eighty":-3.577828,"marketCap":603991092},{"date":"2024-07-12","current":-3.798947,"twenty":-4.001025,"median":-3.825051,"eighty":-3.577828,"marketCap":641319297},{"date":"2024-07-15","current":-3.405847,"twenty":-3.980142,"median":-3.798947,"eighty":-3.577828,"marketCap":574958044},{"date":"2024-08-02","current":-4.08515,"twenty":-4.063676,"median":-3.825051,"eighty":-3.577828,"marketCap":689634611},{"date":"2024-08-09","current":-3.930629,"twenty":-4.063676,"median":-3.914533,"eighty":-3.58397,"marketCap":663549141},{"date":"2024-08-16","current":-3.699952,"twenty":-4.025518,"median":-3.855481,"eighty":-3.617622,"marketCap":699416662},{"date":"2024-08-23","current":-3.709695,"twenty":-3.973459,"median":-3.817957,"eighty":-3.659922,"marketCap":701258562},{"date":"2024-08-30","current":-3.67516,"twenty":-3.943506,"median":-3.741353,"eighty":-3.65762,"marketCap":694730166},{"date":"2024-09-06","current":-3.390241,"twenty":-3.930629,"median":-3.739914,"eighty":-3.608539,"marketCap":640870897},{"date":"2024-09-13","current":-3.240587,"twenty":-3.915649,"median":-3.699952,"eighty":-3.511116,"marketCap":612581180},{"date":"2024-09-20","current":-3.272245,"twenty":-3.914533,"median":-3.679477,"eighty":-3.395997,"marketCap":618565543},{"date":"2024-09-27","current":-3.444923,"twenty":-3.859807,"median":-3.655014,"eighty":-3.33556,"marketCap":651207524},{"date":"2024-10-04","current":-2.886598,"twenty":-3.851156,"median":-3.617387,"eighty":-3.295269,"marketCap":545665119},{"date":"2024-10-11","current":-2.961425,"twenty":-3.850149,"median":-3.577828,"eighty":-3.211808,"marketCap":559809977},{"date":"2024-10-18","current":-3.200296,"twenty":-3.817957,"median":-3.47802,"eighty":-3.18015,"marketCap":604964718},{"date":"2024-10-25","current":-3.444923,"twenty":-3.798947,"median":-3.465068,"eighty":-3.200296,"marketCap":651207524},{"date":"2024-10-31","current":-3.231953,"twenty":-3.752872,"median":-3.462191,"eighty":-3.209506,"marketCap":610949081},{"date":"2024-11-08","current":-3.367218,"twenty":-3.741353,"median":-3.447801,"eighty":-3.218715,"marketCap":636518633},{"date":"2024-11-15","current":-2.144174,"twenty":-3.741353,"median":-3.444923,"eighty":-3.209506,"marketCap":511972947},{"date":"2024-11-22","current":-2.15101,"twenty":-3.739051,"median":-3.433411,"eighty":-3.073089,"marketCap":513605166},{"date":"2024-11-29","current":-2.109995,"twenty":-3.736748,"median":-3.419021,"eighty":-3.008623,"marketCap":503811848},{"date":"2024-12-06","current":-1.964163,"twenty":-3.720056,"median":-3.405847,"eighty":-2.970059,"marketCap":468991158},{"date":"2024-12-13","current":-1.989228,"twenty":-3.703849,"median":-3.378729,"eighty":-2.667081,"marketCap":474975964},{"date":"2024-12-20","current":-1.966442,"twenty":-3.691984,"median":-3.312536,"eighty":-2.153744,"marketCap":469535232},{"date":"2024-12-27","current":-1.916313,"twenty":-3.685521,"median":-3.301025,"eighty":-2.142807,"marketCap":457565620},{"date":"2025-01-03","current":-1.873019,"twenty":-3.682067,"median":-3.286635,"eighty":-2.0626,"marketCap":447228227},{"date":"2025-01-10","current":-1.752253,"twenty":-3.67516,"median":-3.266489,"eighty":-2.0029,"marketCap":418392344},{"date":"2025-01-17","current":-1.775039,"twenty":-3.672282,"median":-3.247782,"eighty":-1.966442,"marketCap":423833077},{"date":"2025-01-24","current":-1.497048,"twenty":-3.658468,"median":-3.227637,"eighty":-1.954138,"marketCap":357456138},{"date":"2025-01-31","current":-1.531227,"twenty":-3.654166,"median":-3.211808,"eighty":-1.919959,"marketCap":365617237},{"date":"2025-02-07","current":-1.501605,"twenty":-3.631778,"median":-3.162882,"eighty":-1.882133,"marketCap":358544284},{"date":"2025-02-14","current":-1.162092,"twenty":-3.62163,"median":-3.070787,"eighty":-1.832004,"marketCap":277477367},{"date":"2025-02-21","current":-1.168928,"twenty":-3.613315,"median":-3.018984,"eighty":-1.784609,"marketCap":279109587},{"date":"2025-02-28","current":-1.064112,"twenty":-3.590112,"median":-2.978693,"eighty":-1.743594,"marketCap":254082217},{"date":"2025-03-07","current":-1.162092,"twenty":-3.577828,"median":-2.970059,"eighty":-1.696654,"marketCap":277477367},{"date":"2025-03-14","current":-1.045883,"twenty":-3.561975,"median":-2.844868,"eighty":-1.612801,"marketCap":249729630},{"date":"2025-03-21","current":-0.660137,"twenty":-3.530406,"median":-2.358363,"eighty":-1.527581,"marketCap":194234157},{"date":"2025-03-28","current":-0.869088,"twenty":-3.513232,"median":-2.153288,"eighty":-1.493402,"marketCap":255714436},{"date":"2025-04-04","current":-1.579152,"twenty":-3.504209,"median":-2.144174,"eighty":-1.320049,"marketCap":464638572},{"date":"2025-04-11","current":-1.262952,"twenty":-3.478882,"median":-2.109995,"eighty":-1.320049,"marketCap":371602043},{"date":"2025-04-17","current":-0.937506,"twenty":-3.463917,"median":-2.033661,"eighty":-1.195689,"marketCap":275845147},{"date":"2025-04-24","current":-0.870937,"twenty":-3.461615,"median":-2.006318,"eighty":-1.170751,"marketCap":256258510}],"updateTime":1745640576777}}}